Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15;3(12):101405.
doi: 10.1016/j.jacadv.2024.101405. eCollection 2024 Dec.

Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

Vikash Jaiswal  1 , Muhammad Hanif  2 , Yusra Mashkoor  3 , Akash Jaiswal  4   5 , Tanisha Prasad  6 , Kripa Rajak  7 , Muhammad Shahzeb Khan  8   9   10 , Robert J Mentz  11 , Gregg C Fonarow  12
Affiliations

Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

Vikash Jaiswal et al. JACC Adv. .
No abstract available

Keywords: SGLT2 inhibitors; amyloidosis; outcomes; transthyretin amyloid cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

Dr Fonarow has done consulting for Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Johnson & Johnson, Medtronic, Merck, Novartis, and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

References

    1. Writing Committee, Kittleson M.M., Ruberg F.L., et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81(11):1076–1126. - PubMed
    1. Usman M.S., Siddiqi T.J., Anker S.D., et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377–2387. doi: 10.1016/j.jacc.2023.04.034. - DOI - PubMed
    1. TriNetX. https://trinetx.com/
    1. Lang F.M., Teruya S., Weinsaft A., et al. Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety. Eur J Heart Fail. 2024;26(4):938–947. doi: 10.1002/ejhf.3198. - DOI - PMC - PubMed
    1. Porcari A., Cappelli F., Nitsche C., et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411–2422. doi: 10.1016/j.jacc.2024.03.429. - DOI - PubMed

LinkOut - more resources